1,000
Participants
Start Date
December 22, 2022
Primary Completion Date
June 30, 2024
Study Completion Date
December 31, 2032
NT-proBNP
NT-proBNP will be measured in all participants in the Investigational arm. If the level of the NT-proBNP is elevated (≥125pg/mL) participants will undergo a full cart-based transthoracic echocardiogram along with a clinical examination for signs of HF and a HF symptom assessment. Participants with HF identified will be referred to their local HF clinic for ongoing management.
RECRUITING
Glasgow Royal Infirmary, Glasgow
RECRUITING
Queen Elizabeth University Hospital, Glasgow
Collaborators (1)
AstraZeneca
INDUSTRY
NHS Greater Glasgow and Clyde
OTHER